Fig. 4.

TC-2153 reverses hyperlocomotor activity in acute PCP-injected mice. Male C57BL/6 mice (4–6-month old) were administered with vehicle (Veh), TC-2153 (TC, 10 mg/kg, i.p.), or clozapine (Clz, 2 mg/kg, i.p.) followed by control (Veh/Veh) or PCP challenge (7.5 mg/kg, i.p.) for 1 h. Distance traveled every 5 min during the 90-min test period (a), total distance traveled (b), and total stereotypic counts (c) were recorded and analyzed using Activity Monitor (MED Associates). Data were expressed as mean ± SEM, and statistical significance was determined using two-way ANOVA with repeated measures followed by post hoc Bonferroni’s test (for a) or one-way ANOVA with post hoc Bonferroni’s test (for b, c) (*p < 0.05, **p < 0.01; ***p < 0.001, n = 9 C57BL/6 mice per group for a–c)